ClinicalTrials.gg
CompletedNCT05642585Updated Sep 8, 2023

A Study of Single-dose MY008211A in Healthy Adults

A Phase 1 interventional study of MY008211A tablets and Placebo in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Wuhan Createrna Science and Technology Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-08.

Sponsored by Wuhan Createrna Science and Technology Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled May 2022, registered Nov 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Hemoglobinuria, Paroxysmal with a site in China — 21 open to participants now, 29 under way, 11 of them phase 3. Hemoglobinuria, Paroxysmal · China.

Enrollment
16th of 47
63 · median 40
Started
2022
with 3 others
Phase 1
13 of 51
5 open now
Registered
12th of 51
by date
Lead sponsor
8 of 51
Wuhan Createrna Science and Technology Co., Ltd

Among the 51 studies in Hemoglobinuria, Paroxysmal with a site in China, this one is the 16th largest by enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2022, is one of 13 in phase 1, and was the 12th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

21 of the 51 studies in Hemoglobinuria, Paroxysmal with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hemoglobinuria, Paroxysmal with a site in China, or all of them as a file.
02

Study summary

The trial is the first human trial. The safety, tolerability, PK and PD of MY008211A Tablets will be evaluated in healthy subjects.

Read the detailed description

This is a single ascending dose, randomized, double-blind study,with 5 dose groups preset.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.18≤ age ≤ 45, male or female;

2.Body weight: ≥50 kg for male, ≥45 kg for female; (BMI): 19.0-26.0 kg/m2 (inclusive);

3. will be signed before the trial, and the content, process and possible adverse reactions of the trial will be fully understood;

4.The volunteers should be able to communicate well with the researchers and understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. Participants who were enrolled in a clinical trial or used a study drug within 3 months before administration of the study drug;
  2. Patients with chronic or active gastrointestinal diseases such as esophageal disease, gastritis, gastric ulcer, enteritis, active gastrointestinal bleeding, or gastrointestinal surgery within the past three years and still according to the investigator;
  3. Patients with definite diseases of the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, hematological system, metabolic system and other diseases that require medical intervention or are not suitable for clinical trial (such as psychiatric history);
  4. History of known or suspected immunodeficiency (e.g., history of frequent recurrent infections), inherited or acquired complement deficiency;
  5. Patients had a clear history of capsular microbial infection within 6 months before screening; Including but not limited to: Streptococcus pneumoniae, Bacillus anthracis, Salmonella, Salmonella typhi, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, Neisseria meningitidis, Haemophilus influenzae, Legionella pneumophila infection history;
  6. Patients with previous or current history of TB infection;
  7. Active systemic bacterial, viral, or fungal infection within 14 days before administration of the study drug;
  8. Fever (≥ 38 ° C) within 7 days before administration of the study drug;
  9. Those who have a history of allergy to the trial preparation and any of its components or related preparations, or to drugs, foods or other substances;
  10. Those who cannot tolerate intravenous puncture or have a history of syncope or needle sickness;
  11. Patients who underwent surgery within 6 months before the study drug is used, which will be judged by the investigators to affect the absorption, distribution, metabolism, and excretion of the study drug; Surgical procedures within 4 weeks before the use of the study drug; Or planned to undergo a surgical procedure during the trial;
  12. Who had taken any medicine (including Chinese herbal medicine, health products, etc.) within 14 days before administration of the study drug;
  13. Who received a vaccine or within 14 days before administration of the study drug, or who plan to receive a vaccine during the trial;
  14. Who donated blood or lost a large amount of blood (> 400mL) within 3 months before administration of the study drug, received a blood transfusion or use of blood products, or intended to donate blood or blood components during or within 3 months after administration of the study drug;
  15. Drug abusers or had used hard drugs (e.g., cocaine, phencyhexidine, etc.) or soft drugs (e.g., cannabis) within 1 year before administration of the study drug;
  16. Smokers or had smoked more than 5 cigarettes per day in 3 months before study drug use, or will be unable to stop using any tobacco products during the study;
  17. Heavy drinkers, who drink at least twice a day or more than 14 times a week, or are avid binge drinkers (one drink is defined as 125mL of wine, 220mL of beer, or 50mL of liquor; Binge drinking is defined as 5 or more drinks in approximately 2 hours); Or unwillingness to stop drinking alcohol or any alcohol-based product during the trial;
  18. Those who have special requirements for diet and cannot abide by the uniform diet;
  19. Volunteers (or their partners) who plan to be pregnant or donate sperm or eggs during the trial to 3 months after the end of the trial, or who are unwilling to take one or more non-drug measures (such as complete abstinence, condoms, contraceptive rings, surgical sterilization, etc.);
  20. Pregnant or lactating women; Or having unprotected sex within 2 weeks before using the study drug; Or oral contraceptive use within 30 days or long-acting estrogen or progestin injectable or implant use within 6 months before use of the study drug;
  21. Physical examination, , chest X-ray, abdominal ultrasound, vital signs, laboratory examination abnormalities were clinically significant (subject to clinician's judgment);
  22. With positive uremic screening test;
  23. With positive alcohol breath test;
  24. Volunteers may not be able to complete the study for other reasons or have other reasons for not participating in the study as judged by the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Group 1: Dose1

    Participants randomized to receive MY008211A tablets or placebo on Day 1.

    Drug: MY008211A tablets · Drug: Placebo

  • Experimental
    Group 2: Dose2

    Participants randomized to receive MY008211A tablets or placebo on Day 1.

    Drug: MY008211A tablets · Drug: Placebo

  • Experimental
    Group 3: Dose3

    Participants randomized to receive MY008211A tablets or placebo on Day 1.

    Drug: MY008211A tablets · Drug: Placebo

  • Experimental
    Group 4: Dose4

    Participants randomized to receive MY008211A tablets or placebo on Day 1.

    Drug: MY008211A tablets · Drug: Placebo

  • Experimental
    Group 5: Dose5

    Participants randomized to receive MY008211A tablets or placebo on Day 1.

    Drug: MY008211A tablets · Drug: Placebo

  • Experimental
    Group 6: Dose6

    Participants randomized to receive MY008211A tablets or placebo on Day 1.

    Drug: MY008211A tablets · Drug: Placebo

  • Experimental
    Group 7: Dose7

    Participants randomized to receive MY008211A tablets or placebo on Day 1.

    Drug: MY008211A tablets · Drug: Placebo

Interventions

  • Single oral

    Also known as: no name

  • DrugPlacebo

    Single oral

    Also known as: no name

06

What researchers measure

Primary outcomes

  1. The incidence and severity of adverse events to assess safety and tolerability

    such as laboratory abnormalities

    Time frame: up to 21days

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) Of MY008211A tablets

    Maximum Plasma Concentration (Cmax)

    Time frame: up to 72 hours postdose

  2. Time To Reach The Maximum Plasma Concentration (Tmax) Of MY008211A

    The Maximum Plasma Concentration (Tmax)

    Time frame: up to 72 hours postdose

  3. Area Under The Concentration Versus Time Curve (AUC) Of MY008211A

    Area Under The Concentration Versus Time Curve (AUC)

    Time frame: up to 72 hours postdose

  4. Half Life (t1/2) Of MY008211A

    Half Life (t1/2)

    Time frame: up to 72 hours postdose

  5. Changes in serum C3 levels from baseline

    serum C3 levels

    Time frame: up to 72 hours postdose

  6. Changes in serum LDH levels from baseline

    serum LDH levels

    Time frame: up to 72 hours postdose

07

Study locations

1 site
  • The Third Hospital of Changsha
    Changsha, Hunan 410011, China
08

References and documents

Individual participant data

Plan to share: No — Trade secrets

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jun 2023, 12 months.

Of 19 phase 1 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 8, 2022
StartActual
May 27, 2022
Primary completionActual
Jun 4, 2023
CompletionActual
Jun 4, 2023
Last update
Sep 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05642585
Lead sponsor
Wuhan Createrna Science and Technology Co., Ltd
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
May 27, 2022
Primary completion
Jun 4, 2023
Completion
Jun 4, 2023
Last update
Sep 8, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lanoracopan

Start the discussion